AcelRx Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Quarter ended March 31, 2022. The supplied filing identifies the registrant as AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX); this differs from the request metadata naming TALPHERA, INC.
Business context and financial performance
AcelRx is a specialty pharmaceutical company developing and commercializing therapies for medically supervised settings. Its portfolio included U.S. sales of DSUVIA, European DZUVEO through partner Aguettant, the Zalviso program, pre-filled syringe candidates, and nafamostat programs acquired from Lowell Therapeutics.
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Total revenue | $0.442 million | $0.511 million; down 13% |
| DSUVIA sales | $0.442 million | $0.181 million; up 144% |
| Net loss | $8.674 million | $8.956 million |
| Operating loss | $8.995 million | $9.142 million |
| Net loss per share | $0.06 | $0.08 |
| Operating cash used | $8.934 million | $9.708 million |
Product sales were below cost of goods sold, producing a gross loss of approximately $0.342 million, compared with $0.589 million in Q1 2021. No contract or collaboration revenue was recorded in Q1 2022, versus $0.060 million in the prior-year quarter. Research and development expense rose 36% to $1.315 million; selling, general and administrative expense declined 4% to $7.338 million.
Liquidity, debt, and balance sheet
- Cash, cash equivalents and short-term investments totaled $39.349 million at March 31, 2022, down from $51.630 million at December 31, 2021. Management said these resources were expected to fund operations for at least one year from the filing date, but not to fund long-term operations without additional revenue or financing.
- Cash and cash equivalents were $21.822 million; short-term investments were $17.527 million. Current assets were $42.811 million and current liabilities $17.033 million.
- Oxford debt outstanding was approximately $11.4 million; the scheduled maturity date is June 1, 2023. The loan requires at least $5.0 million of unrestricted cash and is secured by substantially all assets, subject to stated exceptions.
- The liability related to the sale of future royalties was $84.615 million. Total liabilities were $110.244 million, total assets $71.971 million, and stockholders’ deficit $38.273 million.
- Common shares outstanding increased from 136.8 million at year-end to 147.1 million at quarter-end, principally including shares issued in the Lowell transaction.
Investing activities provided $20.176 million, primarily from investment maturities, while financing activities used $2.083 million, principally for debt payments. The company reported an accumulated deficit of $482.258 million.
Material changes and unusual items
- DSUVIA revenue increased, but total revenue declined because Q1 2021 included Zalviso sales and royalty/collaboration revenue that did not recur. Grünenthal’s Zalviso rights had reverted to AcelRx in May 2021; no replacement European license had been secured as of the filing.
- On January 7, 2022, AcelRx acquired Lowell and its nafamostat programs. The transaction was accounted for as an asset acquisition, with an $8.819 million in-process research and development asset recorded. Up to $26 million of contingent consideration may be payable upon regulatory and sales milestones; none had been achieved by March 31.
- In May 2022, after quarter-end, the company initiated a reorganization expected to eliminate approximately 40% of employees, with estimated annual savings of $9 million and approximately $0.5 million of severance and related charges expected in Q2 2022.
- The FDA issued a close-out letter on March 28, 2022, concluding its evaluation of AcelRx’s corrective actions related to a 2021 warning letter about DSUVIA promotional materials.
Outlook, risks, and contingencies
- Management described a shift from commercial expansion toward advancing the late-stage development pipeline and said it was discussing potential partnerships to support a more robust DSUVIA commercial plan while reducing company costs. No specific revenue or earnings guidance was provided.
- FDA approval of the installed automated DSUVIA packaging line was expected in the first half of 2023; management anticipates the line could reduce cost of goods sold in 2023 and beyond. Timing and savings remain uncertain.
- COVID-19-related limits on access to hospitals and healthcare facilities, delayed formulary decisions and elective procedures continued to constrain commercial activity. Supply-chain disruption was also identified as a risk.
- Resubmission timing for the Zalviso U.S. NDA depended partly on finalization of FDA opioid approval guidelines. Niyad had FDA Breakthrough Device Designation, and the filing described an IDE submission; its U.S. development and approval remain uncertain.
- A securities class action and four consolidated derivative actions concerned alleged misstatements about DSUVIA marketing disclosures. The company said it believed the suits lacked merit, intended to defend them, and could not estimate a reasonably possible loss.
- AcelRx disclosed Nasdaq’s minimum-bid-price deficiency notice and a compliance deadline of May 31, 2022. Failure to regain compliance could threaten its listing.
- The company warned that it would need additional capital over the longer term. Potential funding through equity, debt, asset monetization or partnerships could be unavailable, costly or dilutive.
Most important facts for investors to verify
- Whether cash burn, DSUVIA sales and available capital support the stated near-term runway, and what financing may be needed thereafter.
- Whether the workforce reduction achieves the expected $9 million annual savings, and the actual restructuring costs.
- Progress and commercial economics of potential DSUVIA partnerships, the DZUVEO launch, and a replacement Zalviso license.
- Regulatory progress and funding requirements for the automated packaging line, Zalviso, Niyad, and other pipeline programs.
- Developments in the securities and derivative litigation, the Oxford debt maturity, and Nasdaq listing compliance.
- Milestone conditions and potential contingent payments arising from the Lowell acquisition.